Liraglutide in Adults With Obesity: A Multicentre, Single-Arm, Post-Marketing Surveillance Study in Taiwan.
Аннотация
INTRODUCTION
This prospective study (NCT06283641) was the first real-world, multicentre, post-marketing surveillance of GLP-1 receptor agonist liraglutide as an adjunct for weight management in adults with obesity in Taiwan.
METHODS
Data were collected from 14 sites at baseline, week 13 and week 26 (February 2024-January 2025). Safety and effectiveness outcomes, including adverse event (AE) incidence proportions (IPs) and body weight (BW) change, were investigated.
RESULTS
Among 259 adults, 61.0% were female (mean ± SD age 42.6 ± 11.3 years, BW 90.4 ± 17.6 kg, BMI 33.0 ± 4.7 kg/m2). Dyslipidaemia (38.2%), hypertension (26.3%), and diabetes (21.2%) were common. Mean daily and maximum doses were 1.4 ± 0.5 and 1.8 ± 0.7 mg/day, respectively. Overall IP of AEs was 11.2%; 90.9% of events were mild. General/injection-site and gastrointestinal events were most frequent. Medication cost (49.0%) was the predominant factor for dose non-escalation. At weeks 13 and 26, mean BW loss was -5.7 ± 3.5 and -8.5 ± 5.7 kg (both p < 0.0001; ≥ 5% BW loss in 58.4% and 76.7%) and mean systolic blood pressure decrease was 9.0 ± 16.7 and 10.4 ± 18.9 mmHg, respectively.
CONCLUSION
Liraglutide at < 3.0 mg/day was well-tolerated, with BW reduction observed over 26 weeks in Taiwanese adults. Medication cost is a barrier to long-term obesity management and a significant consideration for health policies in Taiwan.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.